Therapy-related myelodysplastic syndrome (t-MDS)/AML of recipient origin is rarely reported after allogeneic BMT. Here, we describe the numerous chromosomal aberrations arising in various recipient cells of a patient who developed t-MDS 17 years after allogeneic BMT. Further, we review the relevant literature on t-MDS after allogeneic BMT.
A 4-month-old boy was diagnosed with juvenile myelomonocytic leukemia on the basis of a typical blood-film examination and hypersensitivity to G-CSF and spontaneous colony formation. Cytogenetic analysis revealed that all the BM cells had a 46,XY karyotype. Around 7 months after diagnosis, the patient underwent an unrelated donor BMT from a male donor fully matched for HLA-A, B and DRB1. Conditioning consisted of 12-Gy-fractionated TBI and administration of high-dose etoposide (50 mg/kg Â 1) and Ara-c (3 g/m 2 Â 8); GVHD prophylaxis included the administration of CsA and short-term MTX. Engraftment was uneventful, but the patient developed grade II gastrointestinal GVHD, which was successfully treated with steroids. The patient did not develop chronic GVHD, and his blood cell counts had been normal for 17 years. However, the patient developed pancytopenia at the age of 18 years. A BM aspirate, containing 1.4% leukemia cells, showed hypoplastic marrow with trilineage dysplasia. Chimerism by STR analysis of BM mononuclear cells was 94.9% recipient type. Karyotypic analysis of the BM cells showed a complex clonal chromosomal aberration, 46,XY,t(1;11)(p22;q22),add(1)(p13),del(11)(q23), and three non-clonal abnormal cells ( Table 1) . Rearrangement of the mixed-lineage leukemia gene was not observed. Peripheral blood cultured with PHA for 72 h showed 15 random non-clonal chromosomal aberrations and a normal male karyotype (Table 1) . Furthermore, karyotypic analysis of BM fibroblasts and skin fibroblasts revealed random, non-clonal chromosomal aberrations of 100% recipient origin (Table 1) . Diepoxybutane treatment did not cause chromosomal breakage in the peripheral lymphocytes; this finding suggested that he did not have chromosomal instability syndromes, such as Fanconi anemia. He was diagnosed with t-MDS, and a second BMT from another HLA-matched unrelated donor was performed; 45 months after BMT, the patient is well with 100% second donortype chimerism.
The t-MDS/AML after allogeneic BMT arising from recipient cells is extremely rare; of a total of 8 257 cases of allogeneic BMT, only six cases of t-MDS/AML have been reported. 1 Five cases, including the present case, have been described in detail (Table 2) .
2,3,4,5 These five cases were characterized by hematological malignancy at primary diagnosis, administration of high-dose TBI at BMT, and complex karyotypes, particularly with other complex abnormal clones at the diagnosis of t-MDS in four cases (patient no. 2-5). The risk factors in the development of leukemia from recipient-derived cells may be similar to the risk factors identified in autologous BMT, where exposure to previous therapy, in addition to the conditioning regimen for BMT, may possibly damage the stem cells that survive after transplantation. 6 The use of alkylating agents and topoisomerase II inhibitors are associated with the development of t-MDS/AML and of aberrations in chromosome numbers 5/7 or 11q23 (mixed-lineage leukemia); all five patients had been administered high doses of these agents as part of the conditioning regimen for allogeneic BMT. Most t-MDS/AML patients have a latent Chromosomal instability of recipient origin was also reported in the blood cells of some patients without MDS/AML who underwent allogeneic BMT with TBIbased conditioning regimens. 8, 9 In our case, chromosomal instability was seen in the leukemic cells, lymphocytes and somatic cells, such as skin or BM fibroblasts, but not in the blood cells. Radiotherapy, including TBI, may have been the major cause of chromosomal damage. Such chromosomal aberrations do not immediately affect the patients' outcomes; however, secondary genomic alterations may cause malignant transformation even after 17 years of BMT, as shown in our case.
The prognosis of t-MDS/AML after autologous BMT was very poor, 10 but the prognosis after allogeneic BMT is unknown. Three of the five patients with t-MDS after allogeneic BMT underwent second SCT (Table 2) . Two patients with long latent periods (more than 5 years after BMT), including our patient, could be effectively treated by second SCT, but such intensive therapy may be highly toxic to the patients with short latent periods (less than 1 year after BMT). Roos-Weil et al. reported that t-MDS with complex karyotypes involving chromosome 7 and developing 1 year after BMT could be successfully treated with donor lymphocyte infusions (DLIs). 5 They suggested that early treatment with DLIs might be an effective and well-tolerated therapeutic option. Yoshihara et al. also reported the case of a patient with ALL who showed numerous aberrant chromosomal changes in the recipient cells after allogeneic BMT with TBI regimen and was effectively treated by DLIs 14 months after BMT. 9 Although original leukemic cells, dysplastic changes and abnormal blood cell counts were not found in their case, DLIs were effectively used twice to eradicate the abnormal karyotypes; the mixed chimerism also disappeared completely. Because post-BMT genomic instability may have led to the development of t-MDS/AML, DLIs might be the effective therapy, especially for patients with short latent periods after BMT.
In conclusion, we have shown t-MDS developing 17 years after allogeneic BMT and detection of mixed chimerism with very high percentage of recipient origin; however, the exact time point when the MDS change occurred is still unknown. Because of the elimination of the original juvenile myelomonocytic leukemia clone, the other MDS clone had evolved slowly during residual autologous hematopoietic regeneration after BMT, and the tolerance of donor T cells and/or TBI damage may have resulted in the development of the MDS clone.
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